Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term GROWTH-FACTOR RECEPTOR. Found 11 abstracts

de Bono JS, Piulats JM, Pandha HS, Petrylak DP, Saad F, Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, Wang T, Scranton J, Pollak MN. Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 2014 Apr;20(7):1925-34.   PMCID: No NIH funds
Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R, Nccn. Breast Cancer Version 3.2014 Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2014 Apr;12(4):542-90.   PMCID: No NIH funds
Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuebas L, Seeholzer LF, Nicolas E, Hensley H, Jordan VC, Walker CL, Henske EP. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proceedings of the National Academy of Sciences of the United States of America. 2009 Feb;106(8):2635-40.   PMCID: PMC 2637277
Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG. Association of k-ras mutational status and clinical outcomes in patients with metastatic colorectal. cancer receiving panitumumab alone. Clinical Colorectal Cancer. 2008 May;7(3):184-90.
Hecht JR, Patnaik A, Berlin J, Venook A, Malik L, Tchekmedyian S, Navale L, Amado RG, Meropol NJ. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007 Sep;110(5):980-8.
Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibition in cancer therapy. Expert Opinion on Therapeutic Targets. 2007 Dec;11(12):1587-609.
MacKenzie AR, von Mehren M. Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future. Expert Review of Anticancer Therapy. 2007 Aug;7(8):1145-54.
Nordberg E, Friedman M, Gostring L, Adams GP, Brismar H, Nilsson FY, Stahl S, Glimelius B, Carlsson J. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nuclear Medicine and Biology. 2007 Aug;34(6):609-18.
Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. International Journal of Oncology. 2007 Feb;30(2):509-20.
Weiner LM. Opinion - Building better magic bullets - improving unconjugated monoclonal antibody therapy for cancer. Nature Reviews Cancer. 2007 Sep;7(9):701-6.
Henderson GS, van Diest PJ, Burger H, Russo J, Raman V. Expression pattern of a homeotic gene, HOXA5, in normal breast and in breast tumors. Cellular Oncology. 2006 Jan;28(5-6):305-13.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term GROWTH-FACTOR RECEPTOR

GROWTH-FACTOR RECEPTOR CANCER CETUXIMAB SOLID TUMORS IN-VIVO SURGICAL ADJUVANT BREAST DOUBLE-BLIND CELL LUNG-CANCER OPEN-LABEL Oncology ANTITUMOR-ACTIVITY EGFR CONTROLLED-TRIAL PLUS IRINOTECAN ENDOMETRIAL IGF-IR internalization CCI-779 BREAST-CANCER CELLS SENTINEL-NODE BIOPSY HOMEOBOX GENES PREDNISONE BIOLOGY GROOMING BEHAVIOR MTOR METASTATIC COLORECTAL-CANCER LYMPHANGIOLEIOMYOMATOSIS GASTROINTESTINAL STROMAL TUMORS A431 monoclonal antibodies kinase inhibitor EMISSION TOMOGRAPHY TYROSINE combination therapy breast cancer MECHANISM P70 S6 KINASE FLUOROURACIL epidermal growth factor receptor panitumumab-human monoclonal antibody-colorectal cancer CANCER CELLS ERBB RECEPTORS PLACEBO-CONTROLLED TRIAL MODEL PHASE-I TRIAL homeotic gene neu SARCOMAS RAD001 B-RAF KINASE HYBRIDIZATION ESTROGEN-RECEPTOR MEK GENE ACTIVATION soft-tissue sarcoma QUALITY-OF-LIFE SINGLE-CHAIN FV PATHWAY ACTIVATION BLOCKADE PLUS mammalian target of rapamycin KRAS MUTATION LEUCOVORIN PHASE-II TRIAL BISPECIFIC ANTIBODY PERIPHERAL NERVOUS-SYSTEM B-Raf C-RAF GENE COPY NUMBER retention MONOCLONAL-ANTIBODY transduction FC-GAMMA-RIII radionuclide SOFT-TISSUE PAPILLARY THYROID-CARCINOMA signal cancer INSULIN MICE Ras PHASE-I AROMATASE INHIBITOR ACUTE fulvestrant MAPK anoikis-lymphangioleiomyomatosis-Bim-Rheb MOUSE CLINICAL-TRIALS breast DOMAIN GENE-TRANSCRIPTION INCREASED SURVIVAL IN-SITU HYBRIDIZATION COMPUTED TOMOGRAPHY DISRUPTION SCLEROSIS COMPLEX TAMOXIFEN RESISTANCE HER2 sirolimus C-RAF-1 bone sarcoma c-RAF-1 epidermal growth factor receptor BRAF CYCLOPHOSPHAMIDE affibody molecule antisense inhibitor PHOSPHATIDIC-ACID systems biology MYELOID-LEUKEMIA MAMMALIAN TARGET POOR SURVIVAL HOXB8 PROTEIN HETERODIMERIZATION PIK3CA DOXORUBICIN PLUS SKIN-SPARING MASTECTOMY ANTISENSE OLIGONUCLEOTIDE epidermal growth factor CYSTEINE-RICH DOMAIN RENAL ANGIOMYOLIPOMAS KINASE TUMOR PENETRATION RANDOMIZED-TRIAL RANDOMIZED AP23573 POSTMENOPAUSAL WOMEN ABX-EGF LUNG-CANCER THERAPY 5132 CGP 69846A INHIBITION
Last updated on Saturday, August 08, 2020